The Next Frontier In Obesity: Better, Not More, Weight Loss
R&D leaders from Novo Nordisk, Lilly, Boehringer Ingelheim and others discussed what some of the advances could be in the next generation of obesity medicines.
You may also be interested in...
Novo Nordisk’s Wegovy/Ozempic and Lilly’s Mounjaro were third quarter standouts, but the exploding obesity category was a theme across many of the big pharma company earnings calls.
In this week's podcast edition of Five Must-Know Things: US approval for Lilly’s obesity drug; a look at the future of the obesity market; BMS’s ADC deal; Roche’s MS plans; and one Chinese firm’s CAR-T plans.
The company licensed an oral GLP-1 agonist from Eccogene, hoping to capitalize on its heritage in cardiovascular disease. AstraZeneca also reported third quarter results.